- Elexacaftor/tezacaftor/ivacaftor, sold
under the
brand names Trikafta and Kaftrio, is a fixed-dose
combination medication used to
treat cystic fibrosis...
-
application was filed.
Trikafta is
approved for
approximately 90% of
patients with
cystic fibrosis.
Vertex has
refused to make
Trikafta available in developing...
- the fixed-dose combination, elexacaftor/tezacaftor/ivacaftor (brand name
Trikafta), is used to
treat people with
cystic fibrosis who are
homozygous for the...
- 2019, the
combination drug elexacaftor/ivacaftor/tezacaftor,
marketed as
Trikafta,was
approved for CF
patients over the age of 12 in the
United States. In...
- drug to the
pipeline as
Vertex seals its
domination of the
field with
Trikafta OK". EndpointNews. Hopkins,
Jared S. (February 6, 2023). "AbbVie Aims for...
-
combination of elexacaftor, tezacaftor, and
ivacaftor is
being sold as
Trikafta. In 2019, the U.S. Food and Drug
Administration (FDA)
approved a combination...
-
available in a
combination product with
elexacaftor and
tezacaftor called Trikafta for the
treatment of
people with
cystic fibrosis who have the F508del mutation...
-
Since she
became CEO,
Vertex has
developed cystic fibrosis therapy drug
Trikafta, APOL1-mediated
kidney disease experimental apolipoprotein L1 inhibitor...
- for the
company Vertex Pharmaceuticals,
which makes cystic fibrosis drug
Trikafta.
Stephenson has been a
member of ACT for
nearly 30 years,
since its formation...
- Orkambi,
Symdeko and
Trikafta – the
first medicines to
treat the
underlying cause of
cystic fibrosis. The FDA
approved Trikafta on
October 21, 2019. In...
